Targeting GLI1 and BAX by nanonoscapine could impede prostate adenocarcinoma progression.
Humans
Male
Prostatic Neoplasms
/ drug therapy
Apoptosis
/ drug effects
Adenocarcinoma
/ drug therapy
Cell Line, Tumor
Zinc Finger Protein GLI1
/ metabolism
Cell Proliferation
/ drug effects
bcl-2-Associated X Protein
/ metabolism
Noscapine
/ pharmacology
Nanoparticles
/ chemistry
Gene Expression Regulation, Neoplastic
/ drug effects
Disease Progression
Bioinformatics
Cell cycle arrest
Noscapine nanoparticles
Tumor cell apoptosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 Aug 2024
16 Aug 2024
Historique:
received:
15
12
2023
accepted:
25
06
2024
medline:
17
8
2024
pubmed:
17
8
2024
entrez:
16
8
2024
Statut:
epublish
Résumé
Prostate cancer as a critical global health issue, requires the exploration of a novel therapeutic approach. Noscapine, an opium-derived phthalide isoquinoline alkaloid, has shown promise in cancer treatment thanks to its anti-tumorigenic properties. However, limitations such as low bioavailability and potential side effects have hindered its clinical application. This study introduces nanonoscapine as a novel medication to overcome these challenges, leveraging the advantages of improved drug delivery and efficacy achieved in nanotechnology. We monitored the effects of nanonoscapine on the androgen-sensitive human prostate adenocarcinoma cell line, LNCaP, investigating its impact on GLI1 and BAX genes' expressions, crucial regulators of cell cycle and apoptosis. Our findings, from MTT assays, flow cytometry, and gene expression analyses, have demonstrated that nanonoscapine effectively inhibits prostate cancer cell proliferation by inducing G2/M phase arrest and apoptosis. Furthermore, through bioinformatics and computational analyses, we have revealed the underlying molecular mechanisms, underscoring the therapeutic potential of nanonoscapine in enhancing patient outcomes. This study highlights the significance of nanonoscapine as an alternative or adjunct treatment to conventional chemotherapy, warranting further investigation in clinical settings.
Identifiants
pubmed: 39152150
doi: 10.1038/s41598-024-65968-4
pii: 10.1038/s41598-024-65968-4
doi:
Substances chimiques
Zinc Finger Protein GLI1
0
GLI1 protein, human
0
bcl-2-Associated X Protein
0
Noscapine
8V32U4AOQU
BAX protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18977Informations de copyright
© 2024. The Author(s).
Références
Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10(2), 63–89 (2019).
pubmed: 31068988
pmcid: 6497009
doi: 10.14740/wjon1191
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020).
pubmed: 31912902
doi: 10.3322/caac.21590
Gann, P. H. Risk factors for prostate cancer. Rev. Urol. 4(Suppl 5), S3–S10 (2002).
pubmed: 16986064
pmcid: 1476014
Grozescu, T. & Popa, F. Prostate cancer between prognosis and adequate/proper therapy. J. Med. Life 10(1), 5–12 (2017).
pubmed: 28255369
pmcid: 5304372
Sathianathen, N. J. et al. Landmarks in prostate cancer. Nat. Rev. Urol. 15(10), 627–642 (2018).
pubmed: 30065357
doi: 10.1038/s41585-018-0060-7
Di Minno, A. et al. 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F2α: putative biomarkers to assess oxidative stress damage following robot-assisted radical prostatectomy (RARP). J. Clin. Med. 11(20), 6102 (2022).
pubmed: 36294423
pmcid: 9605140
doi: 10.3390/jcm11206102
Siddiqui, Z. A. & Krauss, D. J. Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy. Transl. Androl. Urol. 7(3), 378–389 (2018).
pubmed: 30050798
pmcid: 6043751
doi: 10.21037/tau.2018.01.06
Perlmutter, M. A. & Lepor, H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev. Urol. 9(Suppl 1), S3-8 (2007).
pubmed: 17387371
pmcid: 1831539
Sandhu, S. et al. Prostate cancer. Lancet 398(10305), 1075–1090 (2021).
pubmed: 34370973
doi: 10.1016/S0140-6736(21)00950-8
Sekhoacha, M. et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 27(17), 5730 (2022).
pubmed: 36080493
pmcid: 9457814
doi: 10.3390/molecules27175730
Rida, P. C. et al. The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications. Med. Res. Rev. 35(5), 1072–1096 (2015).
pubmed: 26179481
pmcid: 4778555
doi: 10.1002/med.21357
Chen, X., Dang, T. T. & Facchini, P. J. Noscapine comes of age. Phytochemistry 111, 7–13 (2015).
pubmed: 25583437
doi: 10.1016/j.phytochem.2014.09.008
Zhou, J. et al. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J. Biol. Chem. 277(19), 17200–17208 (2002).
pubmed: 11864974
doi: 10.1074/jbc.M110369200
Barken, I., Geller, J. & Rogosnitzky, M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res. 28(6A), 3701–3704 (2008).
pubmed: 19189652
Lasagna, L., Owens, A. H. Jr., Shnider, B. I. & Gold, G. L. Toxicity after large doses of noscapine. Cancer Chemother. Rep. 15, 33–34 (1961).
pubmed: 14462566
Ohlsson, S. et al. Noscapine may increase the effect of warfarin. Br. J. Clin. Pharmacol. 65(2), 277–278 (2008).
pubmed: 17875192
doi: 10.1111/j.1365-2125.2007.03018.x
Madan, J. et al. Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells. Colloids Surf. B Biointerfaces 107, 235–244 (2013).
pubmed: 23502046
doi: 10.1016/j.colsurfb.2013.02.010
Ma, Y. et al. Small molecule nanodrugs for cancer therapy. Mater. Today Chem. 4, 26–39 (2017).
doi: 10.1016/j.mtchem.2017.01.004
Mahmoudian, M. & Rahimi-Moghaddam, P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov. 4(1), 92–97 (2009).
pubmed: 19149691
doi: 10.2174/157489209787002524
Mahindroo, N., Punchihewa, C. & Fujii, N. Hedgehog-Gli signaling pathway inhibitors as anticancer agents. J. Med. Chem. 52(13), 3829–3845 (2009).
pubmed: 19309080
pmcid: 2743241
doi: 10.1021/jm801420y
Chen, R. & Overholtzer, M. When BAX doesn’t kill. Cell Cycle 17(4), 412–413 (2018).
pubmed: 29611436
pmcid: 5927683
doi: 10.1080/15384101.2017.1386516
Hong, M. et al. RNA sequencing: new technologies and applications in cancer research. J. Hematol. Oncol. 13(1), 166 (2020).
pubmed: 33276803
pmcid: 7716291
doi: 10.1186/s13045-020-01005-x
Ji, F. & Sadreyev, R. I. RNA-seq: basic bioinformatics analysis. Curr. Protocols Mol. Biol. 124(1), e68–e68 (2018).
doi: 10.1002/cpmb.68
Azarian, M. et al. Design and optimization of noscapine nanosuspensions and study of its cytotoxic effect. J. Biomol. Struct. Dyn. 37(1), 147–155 (2019).
pubmed: 29283030
doi: 10.1080/07391102.2017.1420490
Ali, A. & Kulik, G. Signaling pathways that control apoptosis in prostate cancer. Cancers 13(5), 937 (2021).
pubmed: 33668112
pmcid: 7956765
doi: 10.3390/cancers13050937
Liu, Z. et al. Direct activation of bax protein for cancer therapy. Med. Res. Rev. 36(2), 313–341 (2016).
pubmed: 26395559
doi: 10.1002/med.21379
Bao, Q. & Shi, Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Diff. 14(1), 56–65 (2007).
doi: 10.1038/sj.cdd.4402028
Kocak, C., Kocak, F. A. T. M. A., Ozturk, B., Tekin, G. & Vatansev, H. Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. Bratisl. Lek. Listy 121, 43–50 (2020).
pubmed: 31950839
Quisbert-Valenzuela, E. O. & Calaf, G. M. Apoptotic effect of noscapine in breast cancer cell lines. Int. J. Oncol. 48(6), 2666–2674 (2016).
pubmed: 27081867
doi: 10.3892/ijo.2016.3476
Tian, X. et al. Down-regulation of liver-intestine cadherin enhances noscapine-induced apoptosis in human colon cancer cells. Expert Rev. Anticancer Ther. 17(9), 857–863 (2017).
pubmed: 28622054
doi: 10.1080/14737140.2017.1344097
Yang, Z. R. et al. Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro. Biochem. Biophys. Res. Commun. 421(3), 627–633 (2012).
pubmed: 22546556
doi: 10.1016/j.bbrc.2012.04.079
Xu, G. et al. Noscapine inhibits human hepatocellular carcinoma growth through inducing apoptosis in vitro and in vivo. Neoplasma 63(5), 726–733 (2016).
pubmed: 27468876
doi: 10.4149/neo_2016_509
Liu, M., Luo, X. J., Liao, F., Lei, X. F. & Dong, W. G. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother. Pharmacol. 67, 605–612 (2011).
pubmed: 20490799
doi: 10.1007/s00280-010-1356-3
Heidari, N. et al. Apoptotic pathway induced by noscapine in human myelogenous leukemic cells. Anticancer Drugs 18(10), 1139–1147 (2007).
pubmed: 17893514
doi: 10.1097/CAD.0b013e3282eea257
Chougule, M., Patel, A. R., Sachdeva, P., Jackson, T. & Singh, M. Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer 71(3), 271–282 (2011).
pubmed: 20674069
doi: 10.1016/j.lungcan.2010.06.002
Jackson, T., Chougule, M. B., Ichite, N., Patlolla, R. R. & Singh, M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother. Pharmacol. 63, 117–126 (2008).
pubmed: 18338172
pmcid: 7799395
doi: 10.1007/s00280-008-0720-z
Qian, S. et al. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 12, 985363 (2022).
pubmed: 36313628
pmcid: 9597512
doi: 10.3389/fonc.2022.985363
Kang, R. et al. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 18(4), 571–580 (2011).
pubmed: 21311563
pmcid: 3131912
doi: 10.1038/cdd.2010.191
Yun, C. W. & Lee, S. H. The roles of autophagy in cancer. Int. J. Mol. Sci. 19(11), 3466 (2018).
pubmed: 30400561
pmcid: 6274804
doi: 10.3390/ijms19113466
Loizzo, D. et al. Novel insights into autophagy and prostate cancer: a comprehensive review. Int. J. Mol. Sci. 23(7), 3826 (2022).
pubmed: 35409187
pmcid: 8999129
doi: 10.3390/ijms23073826
Slee, E. A., Keogh, S. A. & Martin, S. J. Cleavage of BID during cytotoxic drug and UV radiation-induced apoptosis occurs downstream of the point of Bcl-2 action and is catalysed by caspase-3: a potential feedback loop for amplification of apoptosis-associated mitochondrial cytochrome c release. Cell Death Differ. 7(6), 556–565 (2000).
pubmed: 10822279
doi: 10.1038/sj.cdd.4400689
Krajewska, M. et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 4(2), 129–140 (2002).
pubmed: 11896568
pmcid: 1550319
doi: 10.1038/sj.neo.7900222
Beurel, E. & Jope, R. S. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol. 79(4), 173–189 (2006).
pubmed: 16935409
pmcid: 1618798
doi: 10.1016/j.pneurobio.2006.07.006
Quinn, L. M. & Richardson, H. Bcl-2 in cell cycle regulation. Cell Cycle 3(1), 6–8 (2004).
doi: 10.4161/cc.3.1.602
Diril, M. K. et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc. Nat. Acad. Sci. 109(10), 3826–3831 (2012).
pubmed: 22355113
pmcid: 3309725
doi: 10.1073/pnas.1115201109
Liao, H., Ji, F. & Ying, S. CDK1: beyond cell cycle regulation. Aging 9(12), 2465–2466 (2017).
pubmed: 29242409
pmcid: 5764383
doi: 10.18632/aging.101348
Guadagno, J. et al. Microglia-derived IL-1β triggers p53-mediated cell cycle arrest and apoptosis in neural precursor cells. Cell Death Dis. 6(6), e1779–e1779 (2015).
pubmed: 26043079
pmcid: 4669832
doi: 10.1038/cddis.2015.151
Nguyen, T. H. et al. A systematic review and meta-analyses of interleukin-1 receptor associated kinase 3 (IRAK3) action on inflammation in in vivo models for the study of sepsis. PLOS ONE 17(2), e0263968 (2022).
pubmed: 35167625
pmcid: 8846508
doi: 10.1371/journal.pone.0263968
Cui, X. et al. NF-κB suppresses apoptosis and promotes bladder cancer cell proliferation by upregulating survivin expression in vitro and in vivo. Sci. Rep. 7(1), 40723 (2017).
pubmed: 28139689
pmcid: 5282527
doi: 10.1038/srep40723
Robbins, D. J., Fei, D. L. & Riobo, N. A. The Hedgehog signal transduction network. Sci. Signal. 5(246), re6 (2012).
pubmed: 23074268
pmcid: 3705708
doi: 10.1126/scisignal.2002906
Mohler, J. Requirements for hedgehog, a segmental polarity gene, in patterning larval and adult cuticle of Drosophila. Genetics 120(4), 1061–1072 (1988).
pubmed: 3147217
pmcid: 1203569
doi: 10.1093/genetics/120.4.1061
Wang, M. & Huang, W. FOXS1 promotes prostate cancer progression through the Hedgehog/Gli1 pathway. Biochem. Pharmacol. 218, 115893 (2023).
pubmed: 37890593
doi: 10.1016/j.bcp.2023.115893
Bora-Singhal, N. et al. Gli1-mediated regulation of Sox2 facilitates self-renewal of stem-like cells and confers resistance to EGFR inhibitors in non-small cell lung cancer. Neoplasia 17(7), 538–551 (2015).
pubmed: 26297432
pmcid: 4547412
doi: 10.1016/j.neo.2015.07.001
Niewiadomski, P. et al. Gli proteins: regulation in development and cancer. Cells 8(2), 147 (2019).
pubmed: 30754706
pmcid: 6406693
doi: 10.3390/cells8020147
Galvin, K. E. et al. Gli1 induces G2/M arrest and apoptosis in hippocampal but not tumor-derived neural stem cells. Stem Cells 26(4), 1027–1036 (2008).
pubmed: 18276799
doi: 10.1634/stemcells.2007-0879
Joost, S. et al. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res. 72(1), 88–99 (2012).
pubmed: 22086851
doi: 10.1158/0008-5472.CAN-10-4621
Azarian, M. et al. Genotoxicity of noscapine nanosuspension prepared by microfluidic reactors on HepG2 cell line. Iran. J. Chem. Chem. Eng. 39(5), 145–155 (2020).
Roche. life science. Roche. Feb 2,2018]; Available from: https://www.lifescience.roche.com/global_en/products/high-pure-rna-isolation-kit.html .
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 25(4), 402–408 (2001).
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Pfaffl, M. W. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res. 29(9), e45–e45 (2001).
pubmed: 11328886
pmcid: 55695
doi: 10.1093/nar/29.9.e45